Skip to main content

Advertisement

Table 1 Some examples of targeted therapies for cancer

From: Biology-driven cancer drug development: back to the future

Drug Brand name Drug target* Cancer types
In clinical use
   Bevacizumab Avastin VEGF Colorectal, non-small cell lung, breast, renal
   Bortezomib Velcade Proteasome Myeloma, lymphoma
   Celecoxib Onsenal COX2 Familial adenomatous polyposis
   Erlotinib Tarceva   
   Gefitinib Iressa EGFR Non-small cell, lung, colorectal, head and neck
   Cetuximab Erbitux   
   Panitumumab Vectibix   
   Imatinib Gleevec   
   Dasatinib Sprycel BCR-ABL, cKIT, PDGFR Leukemia, gastrointestinal
   Nilotinib Tasigna   
   Methotrexate   DHFR Multiple cancer types
   RAD001 Certican mTOR Renal
   Temirolimus Toricel   
   Sorafenib Nexavar VEGFR, RAF, cKIT, PDGFR Renal, hepatic
   Sunitinib Sutent   
   Topotecan Hycamtin Topoisomerase I Multiple cancer types
   Irinotecan Camptosar   
   Trastuzumab Herceptin ERBB2 Breast
   Lapatinib Tykerb HER2, EGFR Breast
   Tamoxifen Nolvadex ERα Breast
   Exemestane Aromasin   
   Anastrozole Arimidex Aromatase cytochrome P450 Breast
   Letrozole Femara   
   Rituximab MabThera CD20 Lymphoma
   Tositumomab Bexxar   
In development
   17AAG   HSP90  
   ABT-737, ABT-263, Obatoclax   BCL-XL, BCL-2  
   Alvocidib   CDKs  
   Olaparib, AG014699   PARP1/2  
   BEZ235   PI3K  
   GRN163L   hTERT  
   Mapatumumab   TRAIL Receptor  
   Nutlin-3   MDM2  
   PLX4032   BRAF  
   GDC-0449   SMO  
   PF-0477736   CHK1  
  1. *Target abbreviations: BCL-2, anti-apoptotic protein BCL-2; BCL-XL, anti-apoptotic protein BCL extra large; BCR-ABL, fusion protein of breakpoint cluster region and tyrosine kinase ABL1; BRAF, protein tyrosine kinase BRAF; CD20, B-cell phosphoprotein CD20; CDKs, cyclin-dependent kinases; CHK1, serine/threonine kinase CHK1; cKIT, tyrosine kinase c-KIT; COX2, cyclooxygenase 2; DHFR, dihydrofolate reductase; EGFR, epidermal growth factor receptor; ERα, estrogen receptor α; HER2, human epidermal growth factor receptor 2; HSP90, heat shock protein 90; hTERT, telomerase reverse transcriptase; MDM2, murine double minute 2; mTOR, mammalian target of rapamycin; PARP1/2, poly(ADP-ribose) polymerase 1/2; PDGFR, platelet-derived growth factor receptor; PI3K, phosphatidylinositol 3-kinase; RAF, small GTPase RAF; SMO, Smoothened; TRAIL receptor, TNF-related apoptosis-inducing ligand receptor; VEGF, vascular endothelial growth factor; VEGFR, VEGF receptor.